Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide
- PMID: 16263229
- DOI: 10.1016/j.ijpharm.2005.09.023
Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide
Abstract
Niosomes have been reported as a possible approach to improve the low corneal penetration and bioavailability characteristics shown by conventional ophthalmic vehicles. Niosomes formed from Span 40 or Span 60 and cholesterol in the molar ratios of 7:4, 7:6 and 7:7 were prepared using reverse-phase evaporation and thin film hydration methods. The prepared systems were characterized for entrapment efficiency, size, shape and in vitro drug release. Stability studies were carried out to investigate the leaching of drug from niosomes during storage. The intraocular pressure (IOP) lowering activity of acetazolamide niosomal formulations in rabbits was measured using ShiØtz tonometer. Histological examination for the corneal tissues of rabbits receiving niosomal formulations was carried out for assessment of the ocular irritancy of niosomes. The results showed that the type of surfactant, cholesterol content and the method of preparation altered the entrapment efficiency and drug release rate from niosomes. Higher entrapment efficiency was obtained with multilamellar niosomes prepared from Span 60 and cholesterol in a 7:6 molar ratio. Niosomal formulations have shown a fairly high retention of acetazolamide inside the vesicles (approximately 75%) at a refrigerated temperature up to a period of 3 months. Each of the tested acetazolamide niosomes prepared by either method produced a significant decrease in IOP compared to the solution of free drug and plain niosomes. Multilamellar acetazolamide niosomes formulated with Span 60 and cholesterol in a 7:4 molar ratio were found to be the most effective and showed prolonged decrease in IOP. Histological examination of corneal tissues after instillation of niosomal formulation for 40 days showed slight irritation in the substantia propria of the eye which is reversible and no major changes in tissues were observed.
Similar articles
-
Development of a topical niosomal preparation of acetazolamide: preparation and evaluation.J Pharm Pharmacol. 2004 Dec;56(12):1509-17. doi: 10.1211/0022357044896. J Pharm Pharmacol. 2004. PMID: 15563757
-
Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.Int J Pharm. 2009 Jul 30;377(1-2):1-8. doi: 10.1016/j.ijpharm.2009.04.020. Epub 2009 Apr 24. Int J Pharm. 2009. PMID: 19394413
-
Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor.Int J Pharm. 2007 Jun 29;338(1-2):21-6. doi: 10.1016/j.ijpharm.2007.01.019. Epub 2007 Jan 19. Int J Pharm. 2007. PMID: 17300885
-
Proniosomes as drug carriers.Pak J Pharm Sci. 2010 Jan;23(1):103-7. Pak J Pharm Sci. 2010. PMID: 20067875 Review.
-
Promising complexes of acetazolamide for topical ocular administration.Expert Opin Drug Deliv. 2010 Aug;7(8):943-53. doi: 10.1517/17425247.2010.497536. Expert Opin Drug Deliv. 2010. PMID: 20565335 Review.
Cited by
-
Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures.Int J Nanomedicine. 2015 Mar 18;10:2191-206. doi: 10.2147/IJN.S75615. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25834433 Free PMC article. Review.
-
Ocular administration of acetazolamide microsponges in situ gel formulations.Saudi Pharm J. 2018 Nov;26(7):909-920. doi: 10.1016/j.jsps.2018.01.005. Epub 2018 Sep 24. Saudi Pharm J. 2018. PMID: 30416345 Free PMC article.
-
Particulate Systems in the Enhancement of the Antiglaucomatous Drug Pharmacodynamics: A Meta-Analysis Study.ACS Omega. 2019 Dec 16;4(26):21909-21913. doi: 10.1021/acsomega.9b02895. eCollection 2019 Dec 24. ACS Omega. 2019. PMID: 31891069 Free PMC article.
-
Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier.Adv Pharmacol Sci. 2018 Dec 11;2018:6847971. doi: 10.1155/2018/6847971. eCollection 2018. Adv Pharmacol Sci. 2018. PMID: 30651728 Free PMC article. Review.
-
Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks.Drug Deliv. 2017 Nov;24(1):932-941. doi: 10.1080/10717544.2017.1337823. Drug Deliv. 2017. PMID: 28617150 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources